Determination of Chlordiazepoxide and Its Metabolites in Plasma by High Pressure Liquid Chromatography

Abstract

A rapid, sensitive and specific high pressure liquid chromatographic (HPLC) assay was developed for the determination of chlordiazepoxide and its metabolites from plasma. The assay involves extraction of chlordiazepoxide and its metabolites into diethyl ether from plasma buffered to pH 9. The overall recovery of chlordiazepoxide is 80 ± 5.0% (S.D.) and the sensitivity limit of detection is 50 to 100 ng/ml of plasma, using a 1 ml specimen. The assay was used in the determination of plasma levels of chlordiazepoxide and its metabolites in man following oral administration of chlordiazepoxide. HCl.

The chromatographic behavior of other clinically important benzodiazepines and their major metabolites is also reported.     

Simultaneous Determination of Chloroquine and Desethylchloroquine in Blood,Plasma and Urine by High-Performance Liquid Chromatography

Abstract

A high-performance liquid chromatographic method is described for the determination of chloroquine and its major metabolite desethylchloroquine in blood, plasma and urine. The procedure employs reversed-phase chromatography, with ultraviolet detection, and chlorpheniramine as an internal standard. One milliliter samples of biologic fluid are extracted in a single step with ether. The method has a sensitivity limit of 5 ng/ml for chloroquine and its metabolite. The applicability of the method is demonstrated by the analysis of blood and plasma samples obtained from rabbits following intravenous administration of chloroquine.     

Determination of the Antimalarial Primaquine in Whole Blood and Urine by Normal-Phase High-Performance Liquid Chromatography

Abstract

A method has been developed to estimate primaquine in whole blood and urine by sensitive and selective high-performance liquid chromatography. Using the linear chain analogue of primaquine as the internal standard, a single-step extraction, normal-phase silica column with a basic mobile phase, levels down to 1 ng/ml of primaquine could be measured with good precision. Other anti-malarials like amodiaquine and pyrimethamine did not interfere in the assay. The major carboxylic acid metabolite of primaquine did not elute under the normal-phase chromatographic conditions. The method is suitable for use in clinical pharmacokinetic studies with primaquine.     

The Determination of a New Trifluorinated Quinolone,Fleroxacin, Its N-Demethyl,and N-Oxide Metabolites in Plasma and Urine by High Performance Liquid Chromatography with Fluorescence Detection

Abstract

A liquid chromatographic method is described for the determination of the new fluoroquinolone Ro 23–6240 and its N-demethyl and N-oxide metabolites in plasma and urine. The three substances were extracted from aqueous solution with dichloromethane/isopropanol containing sodium dodecyl sulphate. After evaporation and reconstitution, samples were analysed on a reversed-phase column using ion pair chromatography and fluorescence detection. The limit of quantification was 10–20 ng/ml (RSD 4%) using a 0.5 ml plasma sample, and the inter assay precision was 3–10% over the concentration range 50 ng/ml to 20 μg/ml. Recovery from plasma was 81% (RSD 10%) over the range 10 ng/ml to 5 μg/ml. The method has been applied successfully to the analysis of several thousand samples from human pharmacokinetic studies. Care has to be taken to avoid exposure of samples to direct sunlight, and the use of opaque vessels for sample storage and handling is recommended.     

Quantitation of Verapamil and Norverapamil in Small Blood Samples From the Rat by High Performance Liquid Chromatography

Abstract

A simple, sensitive HPLC assay using flurescence detection was developed for quantitation of verapamil and its active metabolite, norverapamil in 100-200 μl blood samples from the rat. Baseline separation of verapamil, normverapamil and internal standard, propranolol, was attained within 14 minutes. Standard curves for verapamil and norverapamil were linear from 7 ng/ml to 1000 ng/ml with limit of detection of 4 ng/ml for both Compounds. the intraday and interday coefficients of variation in verapamil and norverapamil concentrations, determined from spiked whole blood samples, were less than 10%.     

Rapid high-pressure liquid chromatographic analysis of verapamil in blood and plasma

A high-pressure liquid chromatographic assay procedure has been developed for verapamil in blood or plasma. A paired-ion solvent system with a reversed-phase column is employed. The procedure is specific for verapamil and the retention times of the major metabolites are identified. This procedure is sensitive to a lower blood concentration of 1 ng/ml and standard curves were found to be linear up to the highest concentration tested, 500 ng/ml. Several drugs were tested for interference with the assay, but none were found to cause any problems. The procedure is simple, rapid and permits the analysis of up to 25 samples per day.     

A Novel Method for the Quantitation of Warfarin and its Metabolites in Plasma

Abstract

A procedure for the rapid, quantitative recovery of warfarin and its metabolites (diastereoisomeric alcohol, 4′-, 6-, 7-, 8-benzylic-hydroxywarfarin and dehydrowarfarin) from plasma with Sep-Pak C₁₈ cartridges has been developed. A solution of warfarin and its metabolites in plasma was acidified with NH₄OAc buffer (pH 4.85), adsorbed on the Sep-Pak C₁₈ resin, washed free of polar constituents and eluted with methanol. Dilution of the eluate with buffer followed by gradient high performance liquid chromatography permitted accurate quantitation of the desired compounds when detected at 313 nm. The recovery of warfarin and each metabolite was greater than 95% over an investigated range of 0.5–10.0 μg/ml of plasma and the limit of quantitation by the assay was 0.1 μg/ml of plasma. For more rapid quantitation of warfarin, without simultaneous analysis of metabolites, the chromatographic parameters were modified so that elution of warfarin occurred within 13 minutes, and the sensitivity of the assay increased to 0.03 μg of warfarin/ml of plasma. The quantitative recovery of warfarin and its metabolites coupled with the chromatographic versatility of the method make it ideally suited for either detailed pharmacokinetic studies or routine plasma analysis of warfarin.     

An HPLC Method for the Determination of Theophylline and Its Metabolites in Serum and Urine

Abstract

A urine and a serum assay have been developed to quantitate theophylline and its major metabolites:1,3-dimethyluric acid, 3-methylxanthine and 1-methyluric acid. Reverse phase chromatography follows a serum acetone extraction procedure and a urine anion exchange clean-up procedure. Lower limits of sensitivity are 0.04 μg/ml for serum metabolites and 1 μg/ml for urine metabolites. Both assays are free of interference from endogenous substances. These assays have been tested successfully in pharmacokinetic and metabolic studies of theophylline.     

Determination of atracurium and laudanosine in human plasma by high-performance liquid chromatography

A high-performance liquid chromatographic method coupled with fluorometric detection has been developed for the determination of atracurium and its major end-product laudanosine in human plasma. The method enables good separation of atracurium from its metabolites after direct precipitation of plasma proteins. The assay is sensitive, reproducible and linear for atracurium concentrations ranging from 31.25 to 8000 ng/ml. In a clinical setting, drugs commonly administered during anesthesia did not interfere with the assay. This method provides a simple and time-saving alternative to existing methods.     

Detection and separation of mitoxantrone and its metabolites in plasma and urine by high-performance liquid chromatography

A high-performance liquid chromatographic method using ion-pair chromatography on reversed-phase C18 material was developed. After sample clean-up on XAD columns, mitoxantrone at concentrations below 1 ng/ml in serum and 0.2 ng/ml in urine were measurable with a coefficient of variation of less than 9.3% at a wavelength of 658 nm. Four metabolites were separated in urine. The two major metabolites co-chromatographed with the synthesized mono- and dicarboxylic acid derivatives of mitoxantrone. The method allowed the measurement of mitoxantrone and its metabolites in serum up to more than one week and in urine up to four weeks after administration of the drug.     

The Determination By Means of Capillary Gas Chromatography of the Benzodiazepines-Clobazam,Clonazepam, Diazepam,and Nitrazepam-and Their Principal Metabolites Currently Used In the Treatment of Epilepsy

Abstract

The authors developed a gas chromatographic method allowing the quantification of those benzodiazepines in current use in the treatment of epilepsy, name ly clobazam, clonazepam, diazepam and nitrazepam. This method involved a butyl acetate extraction from plasma, and an analysis on a CP-Sil 5 WSCOT capillary column with electron-capture detection. Intra-day precision and accuracy were better than 10% for each of the compounds and their main metabolites, N-desmethyldiazepam, oxazepam, N-desraethylclobazam. the quantification limit was about 0.5 to 1 ng/ml for each compound. Linearity proved satisfactory between 1 and 4000 ng/ml. Adequate han previously. Besides, its sensitivity is sufficient for kinetic studies following a single dose administration.     

Analysis of Salicylamide and Its Metabolites in Blood and Urine by HPLC

Abstract

Sensitive liquid chromatographic assays for salicylamide and its metabolites in urine and plasma were developed to facilitate pharmacokinetic studies of the drug's metabolism. The drug and its hydroxylated metabolite, gentisamide, were extracted and concentrated prior to separation on a small-bore reverse-phase column. Conjugated metabolites were assayed separately using reverse-phase ion-pair chromatography. An accurate method of assay calibration in the absence of pure metabolite standards was developed using radioactively-labelled parent drug. In addition one of the metabolites, salicylamide sulfate, was isolated by ion-pair extraction and purified. A significant species difference in salicylamide metabolism was observed. In the dog the drug is almost exclusively (90%) metabolized to its sulfate conjugate, while in humans the glucuronide conjugates of salicylamide (50%) and gentisamide (15%) predominate over salicylamide sulfate (30%).     

Ion-Paired Liquid Chromatographic Method for the Analysis of Pyridostigmine in Plasma

Abstract

A high performance Liquid chromatographic (HPLC) procedure for the analysis of pyridostigmine in plasma has been developed. Only 0.5 ml of plasma is required for the analysis. The clean-up procedure involves a protein precipitation step and a column elution step prior to separation by HPLC. The assay is quite sensitive with a detection limit of 1.37 ng/ml for pyridostigmine in plasma. Variability of results ranged from 3 to 14% on evaluations of assay precision. Accuracy of results, evaluated using blind samples in the range of 0–50 ng/ml, differed between 6 and 12% from blind sample values. Stability was also determined for pyridostigmine in plasma at ?20°C and ?80°C. The results showed no degradation for pyridostigmine at ?80°C for up to four months. In a preliminary study with one human volunteer, the drug could be detected up to 12 hours following oral syrup solution doses of between 0.4 and 0.9 mg/kg. This assay is suitable for pharmacokinetic studies involving pyridostigmine in human subjects.     

High-performance liquid chromatographic determination of spironolactone and its metabolites in human biological fluids after solid-phase extraction.

A simple and sensitive high-performance liquid chromatographic procedure to determine spironolactone and its three major metabolites in biological specimens is described. The assay involves sequential extraction on C18 and CN solid phases, and subsequent separation on a reversed-phase column. In plasma samples, spironolactone and its metabolites were completely separated within 8 min using an isocratic mobile phase, while in urine samples a methanol gradient was necessary to achieve a good separation within 14 min. Recoveries for all analytes were greater than 80% in plasma and 72% in urine. Linear responses were observed for all compounds in the range 6.25-400 ng/ml for plasma and 31.25-2000 ng/ml for urine. The plasma and urine methods were precise (coefficient of variation from 0.8 to 12.5%) and accurate (-12.1% to 7.4% of the nominal values) for all compounds. The assay proved to be suitable for the pharmacokinetic study of spironolactone in healthy human subjects.     

Determination of Saccharin in Plasma and Urine by High Performance Liquid Chromatography

Abstract

A sensitive and specific high performance liquid chromatographic (HPLC) assay for the determination of saccharin in plasma and urine was developed. Saccharin is extracted into diethyl ether at acid pH, evaporated, and reconstituted prior to instrumental analysis. Overall recovery of saccharin is 86.9 + 8.6% and the sensitivity limits of detection is 0.15 μg per ml of plasma or urine using a fluorescence detector. The sensitivity limit in plasma can be extended to 20 ng per ml by use of a 2 ml assay volume and detector attenuation. The assay was used for the determination of saccharin in plasma and urine of rats following oral doses of 5 mg/kg.     

The Use of Thin-Layer Chromatography in Experimental Xenobiology

Abstract

Studies of the metabolism and disposition of most drugs or other xenobiotics share one common feature: the need for an analytical method to measure the xenobiotic and/or its biotransformation products in biosamples. Although chromatographic methods such as GC and HPLC are important and preferred by some laboratories, initial investigations of new xenobiotic entities are often conducted using radiolabeled compounds, and, in such instances, TLC assay methods are frequently selected.

TLC is utilized in xenobiotic metabolism and disposition studies to evaluate the radiochemical purity of labeled xenobiotics, the extent of metabolism, the profile of metabolites in blood and excreta, the concentrations of the xenobiotic and specific metabolites in blood and other biosamples, the stability of the xenobiotic and its metabolites in biosamples, and the relative behavior of metabolites and reference compounds. Preparative TLC is frequently used to isolate specific metabolites. Thin-layer radiochromatography (TLRC) has been utilized to study the pharma-cokinetics of drugs and other xenobiotics in man and in animals. Especially where radiolabeled compounds are used, TLC provides an attractive chromatographic alternative to GC and HPLC in research in experimental xenobiology.     

A Rapid Liquid Chromatographic Method for Determination of Flecainide in Human Blood Plasma Using Ultraviolet Detection

Abstract

A liquid chromatographic method for the assay of the antiarrhythmic drug flecainide in plasma has been developed. The method is rapid, simple and with sufficient detection sensitivity to render it suitable for therapeutic drug monitoring. Flecainide and added internal standard, a non-fluorinated analogue, were extracted by a single ether extraction from alkalinized plasma followed by a back-extraction of the ether with dilute phosphoric acid. A portion of the acid extract was then applied directly to a 30 cm ODS column eluting isocratically with 30% acetonitrile in water containing 0.01M dibutylamine phosphate. Monitoring was by ultraviolet detection at 214 nm and the total run time was 8 min. This method is specific and can quantitate plasma levels to less than 30 ng/ml (free base) from 0.5 ml of plasma without interference from antiarrhythmic drugs commonly used in therapy.     

Sensitive analysis of blood for amodiaquine and three metabolites by high-performance liquid chromatography with electrochemical detection

A high-performance liquid chromatographic method using oxidative electrochemical detection has been developed for selective and sensitive quantification of the antimalarial drug amodiaquine and three of its metabolites in the blood of dosed individuals. The method requires only one extraction step and has detection limits of 1 ng/ml for amodiaquine and its metabolites desethylamodiaquine and bisdesethylamodiaquine and 3 ng/ml for 2-hydroxydesethylamodiaquine. Minor modification of the mobile phase preserves the chromatographic separation and allows ultraviolet spectroscopic detection, which, although appreciably less sensitive, permits monitoring of levels of amodiaquine and the three metabolites in blood and urine samples if an electrochemical detector is unavailable. Levels of amodiaquine and the three metabolites were determined for two volunteers undergoing a nine-week chemoprophylactic regimen in connection with travel to a malarious area. Data are included to compare the in vitro antimalarial activities against three strains of Plasmodium falciparum of amodiaquine and the three metabolites considered.     

Simple and sensitive high-performance liquid chromatographic method for the determination of diltiazem and six of its metabolites in human plasma.

A sensitive, specific and reproducible high-performance liquid chromatographic technique is described for the simultaneous determination in human plasma of diltiazem (DZ) and six of its primary and secondary metabolites which are products of N- and O-demethylation, deacetylation and N-oxidation. The method involves addition of excess KHCO3 to 1 ml of plasma, followed by extraction with 4 ml of ethyl acetate. The organic layer was extracted with 0.01 M HCl and the aqueous layer was dried under nitrogen and then reconstituted with 0.002 M HCl. DZ and its metabolites were free from interference and wer baseline-separated. Calibration curves were linear in the concentration range studied (5-500 ng/ml for all the species). The lower limit of quantification of the assay was 5 ng/ml for DZ and the metabolites. Inter-day and intra-day coefficients of variation were less than 10%. The applicability of this procedure is shown by evaluating the kinetics of DZ and its metabolites in three patients receiving chronic DZ therapy. N-Demethyldiltiazem, deacetyldiltiazem and N-demethyldeacetyldiltiazem were found to be the major metabolites, as previously described. Deacetyldiltiazem N-oxide was found in two of the patients. The other two known but unreported metabolites in human, O-demethyldeacetyldiltiazem and N,O-didemethyldeacetyldiltiazem, were found in the plasma of all three patients.     

Determination of 7-iodo-1,3-dihydro-1-methyl-5(2'-fluorophenyl)-2h-1,4-benzodiazepin-2-one (Ro 7-9957) and its major biotransformation products in blood and urine by electron capture-gas-liquid chromatography.

A sensitive and specific electron capture-gas chromatographic assay was developed for the determination of 7-iodo-1,3-dihydro-1-methyl-5(2'-fluorophenyl)-2H-1,4-benzodiazepin-2-one (I) and its major metabolites in blood and urine. The overall recovery of I and its N-desmethyl metabolite (II) from blood is apparently quantitative. The recovery of the major urinary metabolite, the N-desmethyl-3-hydroxy analog (IV), and the minor metabolites, the N-desmethyl analog (II) and the N-methyl-3-hydroxy analog (III) added to urine as authentic reference standards ranged from 80 to 85%. The sensitivity limits of detection are of the order of 2-3 ng of I and 4-5 ng of II per ml of blood or urine. The method was applied to the determination of blood levels and the urinary excretion pattern in a dog following oral and intravenous administration of a 1-mg/kg dose (total 13 mg), and in man following the intravenous administration of single 5- and 10-mg doses. The N-desmethyl metabolite II was more predominant in dog blood than was the orally or intravenously administered I, but II was barely measurable in human blood.